Hostname: page-component-77f85d65b8-jkvpf Total loading time: 0 Render date: 2026-04-19T03:57:35.320Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect on hearing of ganciclovir therapy for asymptomatic congenital cytomegalovirus infection: four to 10 year follow up

Published online by Cambridge University Press:  30 June 2008

A Lackner ,
A Acham ,
T Alborno ,
M Moser ,
H Engele ,
R B Raggam ,
G Halwachs-Baumann ,
M Kapitan  and
C Walch
A Lackner*
Affiliation:
Department of Neurotology, ENT University Hospital, Graz Medical University, Austria
A Acham
Affiliation:
Department of Neurotology, ENT University Hospital, Graz Medical University, Austria
T Alborno
Affiliation:
Department of Neurotology, ENT University Hospital, Graz Medical University, Austria
M Moser
Affiliation:
Department of Neurotology, ENT University Hospital, Graz Medical University, Austria
H Engele
Affiliation:
Department of Neonatology, Hospital for Paediatrics, Graz Medical University, Austria
R B Raggam
Affiliation:
Institute of Hygiene, Microbiology and Environmental Medicine, Graz Medical University, Austria
G Halwachs-Baumann
Affiliation:
Department of Clinical Chemistry and Laboratory Medicine, Graz Medical University, Austria
M Kapitan
Affiliation:
Institute for Medical Informatics, Statistics and Documentation, Graz Medical University, Austria
C Walch
Affiliation:
Department of Neurotology, ENT University Hospital, Graz Medical University, Austria
*
Address for correspondence: Dr Andreas Lackner, Dept of Neurotology, Medical University Graz, Auenbruggerplatz 26-28, A-8036 Graz, Austria. Fax: +43 316 385 7643 E-mail: andreas.lackner@meduni-graz.at
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Congenital cytomegalovirus infection is the leading identified nongenetic cause of congenital sensorineural hearing loss. Most of the infections are asymptomatic but may be detected from umbilical cord vein and/or newborn serum positivity for human cytomegalovirus immunoglobulin M, and from urine positivity (on polymerase chain reaction) for human cytomegalovirus deoxyribonucleic acid in the newborn period. Children infected by cytomegalovirus may later develop sensorineural hearing loss. In symptomatically infected infants, ganciclovir therapy administered in the neonatal period prevents hearing deterioration. However, preventative therapy of asymptomatic congenital cytomegalovirus disease with ganciclovir is controversial, as side effects such as severe neutropenia may occur during treatment.

Methods:

The study population consisted of 23 asymptomatic children with congenital cytomegalovirus infection. Twelve children were treated just after diagnosis of cytomegalovirus infection in the newborn period, with ganciclovir 10 mg/kg bodyweight for 21 days. The other 11 children were observed without therapy. Over a four to 10 year follow-up period, we evaluated all the children's hearing status using pure tone audiometry.

Results:

All 23 children had normal sensorineural hearing at one year follow up. Five of the 23 children (21.7 per cent) were lost to follow up over the four to 11 year follow-up period. Of the remaining 18 children, sensorineural hearing loss occurred in two (11.1 per cent). Neither child had been treated with ganciclovir in the newborn period. An eight-year-old boy showed bilateral high frequency loss and a 10-year-old girl showed severe unilateral sensorineural hearing loss. In the ganciclovir-treated group (nine children), none showed sensorineural hearing loss. During ganciclovir therapy, moderate neutropenia occurred as a side effect in two out of 12 (16.6 per cent) treated children. Speech and general development were normal in all children.

Conclusion:

Asymptomatic congenital cytomegalovirus infection is likely to be a leading cause of sensorineural hearing loss in young children. Intravenous ganciclovir therapy seems to offer a medical option to prevent subsequent sensorineural hearing loss. Further studies including a greater number of children are needed. Cytomegalovirus screening models are mandatory if medical therapy is to be implemented in time.

Keywords

Sensorineural DeafnessChildCytomegalovirusGanciclovir

Information

Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 123 , Issue 4 , April 2009 , pp. 391 - 396
Copyright
Copyright © JLO (1984) Limited 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1 Dahle, AJ, Fowler, KB, Wright, JD, Boppana, SB, Britt, WJ, Pass, RF et al. Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J Am Acad Audiol 2000;11:283–90Google ScholarPubMed
2 Fowler, KB, Dahle, AJ, Boppana, SB, Pass, RF. Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed? J Pediatr 1999;135:60–4CrossRefGoogle ScholarPubMed
3 Halwachs-Baumann, G, Genser, B, Danda, M, Engele, H, Rosegger, H, Fölsch, B et al. Screening and diagnosis of congenital cytomegalovirus infection: a 5-y study. Scand J Infect Dis 2000;32:137–42Google ScholarPubMed
4 Halwachs-Baumann, G. The congenital cytomegalovirus infection: virus-host interaction for defence and transmission. Curr Pharm Biotechnol 2006;7:303–12CrossRefGoogle ScholarPubMed
5 Andersen, HK, Brostrom, K, Hansen, KB, Leerhoy, J, Pedersen, M, Osterballe, O et al. A prospective study on the incidence and significance of congenital cytomegalovirus infection. Acta Paediatr Scand 1979;68:329–36CrossRefGoogle ScholarPubMed
6 Stagno, S, Pass, RF, Reynolds, DW, Moore, MA, Nahmias, AJ, Alford, CA. Comparative study of diagnostic procedures for congenital cytomegalovirus infection. Pediatr 1980;65:251–7CrossRefGoogle ScholarPubMed
7 Demmler, GJ. Infectious Diseases Society of America and Centers for Disease Control: summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis 1991;13:315–29CrossRefGoogle Scholar
8 Williamson, WD, Desmond, MM, LaFevers, N, Taber, LH, Catlin, FI, Weaver, TG. Symptomatic congenital cytomegalovirus: disorders of language, learning and hearing. Am J Dis Child 1982;136:902–5CrossRefGoogle ScholarPubMed
9 Fowler, KB, McCollister, , Dahle, AJ, Boppana, S, Britt, WJ, Pass, RF et al. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr 1997;130:624–30CrossRefGoogle ScholarPubMed
10 Barbi, M, Binda, S, Caroppo, S, Ambrosetti, U, Corbetta, C, Sergi, P. A wider role for congenital cytomegalovirus infection in sensorineural hearing loss. Pediatr Infect Dis J 2003;22:39–42CrossRefGoogle ScholarPubMed
11 Bauer, P, Parizi-Robinson, M, Roland, P, Yegappan, S. Cytomegalovirus in the perilymphatic fluid. Laryngoscope 2005;115:223–5CrossRefGoogle ScholarPubMed
12 Boppana, SB, Fowler, KB, Pass, RF, Rivera, LB, Bradford, RD, Lakeman, FD et al. Congenital cytomegalovirus infection: association between virus burden in infancy and hearing loss. J Pediatr 2005;145:817–23CrossRefGoogle Scholar
13 Kimberlin, DW, Chin-Yu, Lin, Sanchez, PJ, Demmler, GJ, Dankner, W, Shelton, M et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003;143:16–25CrossRefGoogle Scholar
14 Whitely, RJ, Cloud, G, Gruber, W, Storch, GA, Demmler, GJ, Jacobs, RF et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. J Infect Dis 1997;175:1080–6CrossRefGoogle Scholar
15 Nigro, G, Scholz, H, Bartmann, U. Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: a two regimen experience. J Pediatr 1994;124:318–22CrossRefGoogle ScholarPubMed
16 Österreichische Apotheker Verlagsgesellschaft m.b.H., Wien 2004. Cymevene “Roche” Trockensubstanz zur Infusionsbehandlung, Austrian Codex Fachinformation, 2004/2005;1:1538-1541 ISBN:3852001633Google Scholar
17 Schleiss, MR, Heineman, TC. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 2005;4:381–406CrossRefGoogle ScholarPubMed
18 Roberton, AG. Textbook of Neonatology, 4th edn. London: Elsevier, 2004Google Scholar
19 Michaels, MG, Greenberg, DP, Sabo, DL, Wald, ER. Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatr Inf Dis J 2003;22:504–8CrossRefGoogle ScholarPubMed
20 Bradford, R, Cloud, G, Lakeman, A, Boppana, S, Kimberlin, DW, Jacobs, R et al. Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system. J Infect Dis 2005;191:227–33CrossRefGoogle ScholarPubMed
21 Lazzarotto, T, Guerra, B, Lanari, M, Gabrielli, L, Landini, MP. New advances in the diagnosis of congenital cytomegalovirus infection. J Clin Virol 2008; 41(3): 192–97CrossRefGoogle ScholarPubMed
22 Jacquemard, F, Yamamoto, M, Costa, JM, Romand, S, Jaqz-Aigrin, E, Dejean, A et al. Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. BJOG 2007;114:1113–21CrossRefGoogle ScholarPubMed
23 Nigro, G, Adler, SP, La Torre, R, Best, AM. (Congenital Cytomegalovirus Collaboration Group). Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005;353:1350–62CrossRefGoogle ScholarPubMed
24 Sato, A, Hirano, H, Miura, H, Hosoya, N, Ogawa, M, Tanaka, T. Intrauterine therapy with cytomegalovirus hyperimmunoglobulin for a fetus congenitally infected with cytomegalovirus. J Obstet Gynaecol Res 2007;33:718–21CrossRefGoogle ScholarPubMed